Full text
Earnings transcript
Read the complete earnings call transcript.
PEN
Penumbra, Inc.
$321.06
0.99
(0.31%)
| Exchange: | NYSE |
| Market Cap: | 12.628B |
| Shares Outstanding: | 24.511M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Devices | |||||
| CEO: | Adam Elsesser | |||||
| Full Time Employees: | 4500 | |||||
| Address: |
| |||||
| Website: | https://www.penumbrainc.com |
Penumbra, Inc., founded in 2004 and headquartered in Alameda, California, is a global medical device company specializing in the design, development, manufacture, and sale of innovative healthcare products. The company offers a comprehensive portfolio addressing a wide range of medical needs, particularly in neurovascular and peripheral vascular interventions. Its offerings include advanced aspiration-based thrombectomy systems like the Penumbra System, marketed under various brands such as Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE, which are designed for mechanical thrombectomy, along with the Indigo System for broader vascular applications. For neurovascular conditions, Penumbra provides embolization coiling systems, including the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil, used to treat aneurysms and other neurovascular lesions. Additionally, they offer neurovascular access systems, such as Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM, which enable intracranial access for various therapies. The product line also features neurosurgical aspiration tools like the Artemis Neuro Evacuation Device for tissue and fluid removal, and detachable embolic coil systems (Ruby Coil and Ruby LP) for peripheral embolization. Furthermore, Penumbra supplies microcatheters under the LANTERN brand for delivering coils and occlusion devices, as well as detachable, microcatheter-deliverable occlusion devices (POD – Penumbra Occlusion Device) primarily for occluding peripheral vessels. Complementary devices like Packing Coil and Packing Coil LP are also available for vessel occlusion. Beyond interventional devices, Penumbra develops immersive computer-based technologies for therapeutic purposes, such as the Real Immersive System, which aims to promote health, motor function, and cognitive improvement. The company distributes its products internationally through both its dedicated direct sales organizations and a network of distributors.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 1,058,522 | 1,194,615 | 1,403,665 |
| Gross Profit | 682,643 | 754,995 | 942,437 |
| EBITDA | 108,646 | 45,989 | 222,596 |
| Operating Income | 73,551 | 9,279 | 189,249 |
| Net Income | 90,954 | 14,012 | 177,687 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 1,556,305 | 1,533,181 | 1,826,519 |
| Total Liabilities | 377,361 | 382,250 | 398,916 |
| Total Stockholders Equity | 1,178,944 | 1,150,931 | 1,427,603 |
| Total Debt | 234,343 | 223,389 | 219,699 |
| Cash and Cash Equivalents | 167,486 | 324,404 | 186,897 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 97,333 | 168,481 | 238,663 |
| Capital Expenditure | -15,213 | -21,182 | -63,729 |
| Free Cash Flow | 82,120 | 147,299 | 174,934 |
| Net Income | 90,954 | 14,012 | 177,687 |
| Net Change in Cash | 97,628 | 156,918 | -137,507 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2029 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 2,183,110.879 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 2,285,617.575 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 2,238,800 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 150,884.687 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 157,969.390 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 154,733.615 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 306,451.119 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 325,301.374 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 316,692.141 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 1,077,804.924 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 1,128,412.624 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 1,105,298.721 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 8.060 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 8.280 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 7.800 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 5 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 2 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Revenue Growth: Penumbra reported strong revenue of $339.5 million in Q2 2025, reflecting consistent growth as highlighted in the earnings call transcript. This performance aligns with positive industry trends in the medical devices sector, showcasing the company’s ability to capitalize on market demand.
- Innovative Product Portfolio: The earnings call emphasized strategic investments in product development, contributing to sustained growth in key segments. This focus on innovation positions Penumbra as a leader within its industry, as evidenced by strong gross profit margins (specific figures to be derived from Key Metrics data).
- Solid Financial Position: High operating cash flow and free cash flow (as per Cash Flow Statements data) indicate operational efficiency and the ability to fund further investments without excessive reliance on external financing, providing a strong financial foundation.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates PEN intrinsic value between $55.20 – $650.28 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about PEN valuation
Is Penumbra, Inc. (PEN) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Penumbra, Inc. (PEN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is PEN a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether PEN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is PEN’s P/E ratio?
You can see PEN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for PEN?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is PEN a good long-term investment?
Whether PEN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
PEN
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
0.31
Trading Metrics:
| Open: | 320.77 | Previous Close: | 320.07 | |
| Day Low: | 320.4 | Day High: | 322.09 | |
| Year Low: | 221.26 | Year High: | 362.41 | |
| Price Avg 50: | 326.33 | Price Avg 200: | 305.36 | |
| Volume: | 385404 | Average Volume: | 526412 |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freePEN full analysis
Welcome to MARKETSNAP’s SWOT analysis for Penumbra, a name that might not be on everyone’s radar but definitely deserves a closer look if you’re hunting for growth in the healthcare space. Today, we’re diving deep into what makes this company tick, breaking down its strengths, weaknesses, opportunities, and threats, all while keeping an eye on how it fits into a long-term investment strategy. So, grab a coffee, let’s chat about Penumbra, and see if it’s a potential gem for your…
